8-K: Disc Medicine Reports Positive Q1 2025 Financial Results and Advances Clinical Programs

Disc Medicine reports a strong financial position with $695 million in cash and progress across its pipeline, including plans to submit an NDA for bitopertin in H2 2025.

Summary

• Disc Medicine announced its Q1 2025 financial results and provided a corporate update on May 7, 2025.
• The company is on track to submit an NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025.
• Disc Medicine initiated the APOLLO trial, a confirmatory clinical trial of bitopertin in adults and adolescents with EPP.
• A Phase 2 study of DISC-3405 in polycythemia vera (PV) is planned for initiation in H1 2025.
• Data readouts for the DISC-0974 program are expected in H2 2025, including initial results from the Phase 2 anemia of myelofibrosis (MF) study and multiple dose data from the Phase 1b anemia of non-dialysis dependent chronic kidney disease (NDD-CKD) study.
• The company's financial position is strong, supported by a $259 million public offering in January 2025.
• Disc Medicine ended Q1 with $695 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028.
• The company will host a virtual MF Anemia KOL Day on May 9, 2025.
• R&D expenses for Q1 2025 were $27.8 million, compared to $23.7 million for Q1 2024.
• SG&A expenses for Q1 2025 were $12.2 million, compared to $7.8 million for Q1 2024.
• Net loss for Q1 2025 was $34.1 million, compared to $26.9 million for Q1 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with a strong cash position, progress in clinical trials, and anticipated milestones. The increase in net loss is a concern, but the overall tone is optimistic.

Positives

• The company is on track to submit an NDA for bitopertin in EPP in H2 2025.
• The APOLLO trial has been initiated.
• A Phase 2 study of DISC-3405 in PV is planned for initiation in H1 2025.
• Data readouts for the DISC-0974 program are expected in H2 2025.
• The company has a strong financial position with $695 million in cash, cash equivalents, and marketable securities.
• Cash runway is expected to fund operations into 2028.
• Successful manufacturing-focused end-of-Phase 2 meeting with the FDA's Office of Pharmaceutical Quality (OPQ) achieved alignment on proposed Chemistry, Manufacturing, and Controls (CMC) components of the NDA package.

Negatives

• Net loss for Q1 2025 was $34.1 million, compared to $26.9 million for Q1 2024.
• The increase in net loss was primarily due to higher operating costs to support the continued advancement of the pipeline.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including the adequacy of Disc's capital, the difficulty in predicting the time and cost of development of Disc's product candidates, and the timing of clinical trials and data availability.
• Clinical trial results may not be predictive of future results and may not support further development and marketing approval.

Future Outlook

Disc Medicine expects to submit an NDA for bitopertin in EPP in H2 2025, initiate a Phase 2 study of DISC-3405 in PV in H1 2025, and expects data readouts for the DISC-0974 program in H2 2025. The company's cash is expected to fund operations into 2028.

Management Comments

• 2025 is off to a strong start for Disc as we continue to make operational progress across our portfolio.
• We believe that bitopertin has the potential to be a life-altering therapy and thank the EPP physician, advocate, and patient communities for their ongoing enthusiasm and partnership in the development process.
• Backed by a solid financial foundation which provides a cash runway into 2028, we are well-positioned to progress our commercial preparation efforts for bitopertin as well as development of the rest of our pipeline.

Industry Context

Disc Medicine is focused on hematologic diseases, a competitive area with significant unmet need. The company's pipeline targets heme biosynthesis and iron homeostasis, which are fundamental biological pathways of red blood cell biology. Success in these areas could position Disc Medicine as a leader in the treatment of hematologic disorders.

Comparison to Industry Standards

• Many biopharmaceutical companies in the hematology space, such as Agios Pharmaceuticals and Global Blood Therapeutics (now part of Pfizer), focus on specific hematologic disorders.
• Disc Medicine's approach of targeting fundamental biological pathways of red blood cell biology is similar to that of companies like Protagonist Therapeutics, which is developing hepcidin mimetics.
• The $695 million cash position provides a strong foundation for clinical development, comparable to other well-funded biotech companies in the space.

Stakeholder Impact

• Shareholders: The strong financial position and progress in clinical trials are positive for shareholders.
• Patients: The development of new treatments for hematologic diseases has the potential to improve patient outcomes.
• Employees: The company's growth and development provide opportunities for employees.

Next Steps

• Submit NDA for bitopertin in EPP in H2 2025.
• Initiate Phase 2 study of DISC-3405 in PV in H1 2025.
• Release data readouts for DISC-0974 program in H2 2025.
• Host virtual MF Anemia KOL Day on May 9, 2025.

Key Dates

Keywords

Disc Medicine, bitopertin, DISC-0974, DISC-3405, erythropoietic protoporphyria, EPP, polycythemia vera, PV, myelofibrosis, MF, anemia, NDD-CKD, clinical trials, NDA, financial results, hematologic diseases